

# A Retrospective Chart Review to Assess the Safety Profile of the 755 nm Alexandrite Picosecond Laser with the Diffractive Lens Array (DLA) in Fitzpatrick Skin Types IV-VI

Adele Haimovic, MD, Jeremy A. Brauer, MD, Roy G. Geronemus, MD

## Study Design:

- Retrospective study of 56 subjects treated.
- A 6 mm spot and DLA with fluence of 0.71J/cm<sup>2</sup> was used.
- Standard B&A clinical photos were assessed for dyspigmentation, erythema, edema, and herpetic lesions.
- Average age 33.7 years old.

## Results:

- Average number of treatments was 3.20.
- 1 patient (2.20%) had hyperpigmentation lasting 2 months post treatment.
- 2 patients (4.35%) reported ongoing hyperpigmentation at their initial 1 week follow-up but were not able to be contacted 3 weeks post.
- Transient dyspigmentation, erythema, edema, crusting, and scabbing were seen immediately post treatment and typically resolved within 2 weeks.

## Conclusion:

- 46 subjects receiving treatments with the picosecond alexandrite laser with the DLA had a low rate of prolonged adverse events (2.20%).
- The device is a safe and effective treatment option for unwanted scars, pigmented lesions and striae in patients with Fitzpatrick skin types IV-VI.



Pre-Treatment

3 Months Post 6 Tx



Pre-Treatment

3 Months Post 6 Tx